scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1009647689 |
P356 | DOI | 10.1186/1756-0500-7-109 |
P953 | full work available at URL | https://bmcresnotes.biomedcentral.com/track/pdf/10.1186/1756-0500-7-109.pdf |
P932 | PMC publication ID | 3938033 |
P698 | PubMed publication ID | 24568634 |
P5875 | ResearchGate publication ID | 260380563 |
P50 | author | Megan Smith | Q57071587 |
Karen Canfell | Q70389126 | ||
P2860 | cites work | Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. | Q50758405 |
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. | Q51320990 | ||
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. | Q51490108 | ||
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. | Q51903894 | ||
Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity | Q57089351 | ||
Fall in Human Papillomavirus Prevalence Following a National Vaccination Program | Q61411610 | ||
A revision of sexual mixing matrices in models of sexually transmitted infection | Q84677343 | ||
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data | Q30618714 | ||
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data | Q33743738 | ||
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program | Q34017208 | ||
Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register | Q34051352 | ||
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial | Q34342056 | ||
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine | Q35268615 | ||
Modeling preventative strategies against human papillomavirus-related disease in developed countries | Q37198208 | ||
The predicted impact of vaccination on human papillomavirus infections in Australia | Q37219650 | ||
Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia | Q37876979 | ||
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study | Q44222617 | ||
Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence | Q44504801 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P304 | page(s) | 109 | |
P577 | publication date | 2014-02-25 | |
P1433 | published in | BMC Research Notes | Q15762797 |
P1476 | title | Testing previous model predictions against new data on human papillomavirus vaccination program outcomes | |
P478 | volume | 7 |
Q38223242 | Factors impacting HPV vaccination: lessons for health care professionals |
Q41114449 | Factors related to vaccine uptake by young adult women in the catch-up phase of the National HPV Vaccination Program in Australia: Results from an observational study. |
Q40470651 | HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. |
Q36251151 | Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia |
Q52745312 | Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. |
Q49644195 | Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia |
Q38380092 | The next steps in cervical screening |
Q40569845 | Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries |
Search more.